These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36017268)

  • 21. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
    Zhang K; Li C; Liu Y; Li L; Ma X; Meng X; Feng D
    Neuroradiology; 2007 Nov; 49(11):913-9. PubMed ID: 17763847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-tumor histogram analysis of synthetic magnetic resonance imaging predicts isocitrate dehydrogenase mutation status in gliomas.
    Ge X; Gan T; Yang Z; Liu G; Hu W; Ma W; Bai Y; Xiong Y; Li M; Zhao J; Zhou L; Li J; Li D; Wang X; Zhang J
    Quant Imaging Med Surg; 2024 Mar; 14(3):2225-2239. PubMed ID: 38545061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Nomogram Modeling
    Zhou W; Zhou Z; Wen J; Xie F; Zhu Y; Zhang Z; Xiao J; Chen Y; Li M; Guan Y; Hua T
    Front Oncol; 2020; 10():1200. PubMed ID: 32850348
    [No Abstract]   [Full Text] [Related]  

  • 30. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas.
    Sahu A; Patnam NG; Goda JS; Epari S; Sahay A; Mathew R; Choudhari AK; Desai SM; Dasgupta A; Chatterjee A; Pratishad P; Shetty P; Moiyadi AA; Gupta T
    J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Adult-Type Astrocytic Tumors Using Diffusion Tensor Imaging and
    Yasuda S; Yano H; Ikegame Y; Ikuta S; Maruyama T; Kumagai M; Muragaki Y; Iwama T; Shinoda J; Izumo T
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond T2-FLAIR mismatch sign in isocitrate dehydrogenase mutant 1p19q non-codeleted astrocytoma: Analysis of tumor core and evolution with multiparametric magnetic resonance imaging.
    Jen JP; Li X; Patel M; Haq H; Pohl U; Nagaraju S; Wykes V; Sanghera P; Watts C; Sawlani V
    Neurooncol Adv; 2024; 6(1):vdae065. PubMed ID: 39071736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
    Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
    Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of PET/CT with
    Ogawa T; Kawai N; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2020 May; 10(1):44. PubMed ID: 32382870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance spectroscopic correlates of progression free and overall survival in "glioblastoma, IDH-wildtype, WHO grade-4".
    Sacli-Bilmez B; Danyeli AE; Yakicier MC; Aras FK; Pamir MN; Özduman K; Dinçer A; Ozturk-Isik E
    Front Neurosci; 2023; 17():1149292. PubMed ID: 37457011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.